Rizatriptan Tablet, Film Coated
Product Images NDC 71335-1352

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan (NDC 71335-1352). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Figure 1)

This is a graph showing the estimated probability of response to treatment with placebo or different doses of Rizatriptan Benzoate Tablets (5mg and 10mg) over time, measured in hours post-dose.*

FDA Label Image

Figure-2 (Figure 2)

The text is describing the estimated probability of remedication or rescue after taking different types of tablets, including a placebo and Rizatriptan Benzoate Tablets in 5 mg and 10 mg doses at various time intervals post-dose.*

FDA Label Image

Label Image (Lbl713351352)

This is a medicine package for Rizatriptan, a drug used to treat migraines. It contains pink capsules each with 10mg of Benzoate. The package consists of two tablets stored at room temperature (20°-25°C/68°-77°F) and should be kept away from children. The manufacturer is Macleods Pharmaceuticals Ltd. The package has an expiration date of MM/YY and an NDC 7133513521 07433101523487.*

FDA Label Image

Fig-5 (Rizatriptan Fct Figure 5)

This is a graph or chart showing the effectiveness of Ruzatriptan Benzoate Orally Disintegrating Tablets compared to a placebo. The X-axis measures time in hours after taking the Stage 2 dose, and the Y-axis measures effectiveness on a scale from 0 to 20.*

FDA Label Image

Rizatriptan-structure (Structure1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.